Affordable Access

Should university students be vaccinated against meningococcal disease in Canada?

Authors
  • De Wals, Philippe1
  • 1 Department of Social and Preventive Medicine, Laval University and National Institute of Public Health, Quebec City, Quebec.
Type
Published Article
Journal
The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses
Publication Date
Jan 01, 2004
Volume
15
Issue
1
Pages
25–28
Identifiers
PMID: 18159440
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To evaluate the benefit and costs of vaccination of university students against invasive meningococcal disease (IMD) in Canada. Published studies were reviewed and a simulation model was used. IMD risk seems to be of low magnitude, but consequences can be dramatic. Over a 10-year period, IMD risk reduction would be slightly greater using a monovalent C conjugate vaccine than a quadrivalent polysaccharide vaccine. From a societal perspective, costs per quality-adjusted life-years gained would be between $135,000 and $698,000, according to epidemiological scenarios and with vaccine purchase prices between $35 and $50 per dose. Economic indices exceed proposed criteria for cost effective public health programs, but from the perspective of students and parents, the cost of vaccination might be worth the benefit.

Report this publication

Statistics

Seen <100 times